Document is current
Any future updates will be listed below
-
Authors
Morimoto, Yukina
Tokumitsu, Ayako
Sone, Takefumi https://orcid.org/0000-0003-3467-679X
Hirota, Yuki
Tamura, Ryota
Sakamoto, Ayuna
Nakajima, Kazunori https://orcid.org/0000-0003-1864-9425
Toda, Masahiro
Kawakami, Yutaka https://orcid.org/0000-0002-0036-1186
Okano, Hideyuki https://orcid.org/0000-0001-7482-5935
Ohta, Shigeki https://orcid.org/0000-0003-2994-4278
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science London (17K07115)
JSPS KAKENHI (JP20H05688)
JSPS KAKENHI (JP16H06482)
JSPS KAKENHI (JP26430074)
- License Information
-
More Information
Article History
Received: 28 January 2022
Revised: 3 May 2022
Accepted: 5 May 2022
First Online: 27 May 2022
Declarations
:
: H.O. is a scientific consultant for San Bio Co. Ltd, Eisai Co. Ltd. and Daiichi Sankyo Co. Ltd. Other authors declare they have no competing financial interest.
: All interventions and animal care procedures were performed by the Laboratory Animal Welfare Act, the Guide for the Care and Use of Laboratory Animals (National Institutes of Health, USA), and the Guidelines and Policies for Animal Surgery provided by the Animal Study Committee of the Keio University and were approved by the Animal Study Committee of Keio University (IRB approval number 12017). Human glioma initiating cells were cultured from human specimens as below [10] following approval from the Ethics Review Subcommittee at Keio University School of Medicine (Approval Number, 20019, Tokyo, Japan).
